Royal Bank of Canada’s Niagen Bioscience NAGE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $553K | Sell |
125,305
-3,952
| -3% | -$21.3K | ﹤0.01% | 4059 |
|
|
2025
Q4 | $823K | Buy |
129,257
+1,665
| +1% | +$11.6K | ﹤0.01% | 3800 |
|
|
2025
Q3 | $1.19M | Buy |
127,592
+55,501
| +77% | +$560K | ﹤0.01% | 3840 |
|
|
2025
Q2 | $1.04M | Sell |
72,091
-39,831
| -36% | -$393K | ﹤0.01% | 3868 |
|
|
2025
Q1 | $773K | Buy |
111,922
+1,305
| +1% | +$8.2K | ﹤0.01% | 3669 |
|
|
2024
Q4 | $587K | Sell |
110,617
-90,143
| -45% | -$494K | ﹤0.01% | 3951 |
|
|
2024
Q3 | $733K | Buy |
200,760
+1,155
| +0.6% | +$3.63K | ﹤0.01% | 3791 |
|
|
2024
Q2 | $545K | Buy |
199,605
+14,579
| +8% | +$48.8K | ﹤0.01% | 3946 |
|
|
2024
Q1 | $644K | Buy |
185,026
+65,984
| +55% | +$122K | ﹤0.01% | 3792 |
|
|
2023
Q4 | $170K | Buy |
119,042
+34,448
| +41% | +$48K | ﹤0.01% | 5241 |
|
|
2023
Q3 | $124K | Sell |
84,594
-352
| -0.4% | -$550 | ﹤0.01% | 5231 |
|
|
2023
Q2 | $133K | Buy |
84,946
+856
| +1% | +$1.28K | ﹤0.01% | 5102 |
|
|
2023
Q1 | $129K | Sell |
84,090
-159
| -0.2% | -$283 | ﹤0.01% | 4975 |
|
|
2022
Q4 | $141K | Buy |
84,249
+8,604
| +11% | +$13.6K | ﹤0.01% | 5191 |
|
|
2022
Q3 | $93K | Buy |
+75,645
| New | +$122K | ﹤0.01% | 5356 |
|
|
2022
Q2 | – | Sell |
-2,880
| Closed | -$7K | – | 7803 |
|
|
2022
Q1 | $7K | Sell |
2,880
-7,237
| -72% | -$19.8K | ﹤0.01% | 7141 |
|
|
2021
Q4 | $38K | Buy |
10,117
+4,635
| +85% | +$25K | ﹤0.01% | 6530 |
|
|
2021
Q3 | $35K | Buy |
5,482
+2,273
| +71% | +$18.7K | ﹤0.01% | 6374 |
|
|
2021
Q2 | $32K | Buy |
3,209
+79
| +3% | +$689 | ﹤0.01% | 6312 |
|
|
2021
Q1 | $29K | Sell |
3,130
-246
| -7% | -$1.95K | ﹤0.01% | 6215 |
|
|
2020
Q4 | $16K | Buy |
3,376
+3,350
| +12,885% | +$16.3K | ﹤0.01% | 6171 |
|
|
2020
Q3 | $0 | Sell |
26
-57
| -69% | -$275 | ﹤0.01% | 6993 |
|
|
2020
Q2 | $0 | Sell |
83
-130
| -61% | -$582 | ﹤0.01% | 6963 |
|
|
2020
Q1 | $1K | Sell |
213
-1,275
| -86% | -$4.9K | ﹤0.01% | 6509 |
|
|
2019
Q4 | $6K | Buy |
1,488
+1,003
| +207% | +$3.56K | ﹤0.01% | 6315 |
|
|
2019
Q3 | $2K | Hold |
485
| – | – | ﹤0.01% | 6322 |
|
|
2019
Q2 | $2K | Hold |
485
| – | – | ﹤0.01% | 6613 |
|
|
2019
Q1 | $2K | Hold |
485
| – | – | ﹤0.01% | 6557 |
|
|
2018
Q4 | $2K | Sell |
485
-695
| -59% | -$2.42K | ﹤0.01% | 6480 |
|
|
2018
Q3 | $5K | Buy |
1,180
+533
| +82% | +$2.29K | ﹤0.01% | 6288 |
|
|
2018
Q2 | $3K | Buy |
647
+162
| +33% | +$615 | ﹤0.01% | 6192 |
|
|
2018
Q1 | $2K | Sell |
485
-104
| -18% | -$545 | ﹤0.01% | 6136 |
|
|
2017
Q4 | $4K | Buy |
589
+583
| +9,717% | +$3.15K | ﹤0.01% | 6146 |
|
|
2017
Q3 | $0 | Buy |
+6
| New | +$22 | ﹤0.01% | 7039 |
|
|
2017
Q2 | – | Sell |
-1,097
| Closed | -$3K | – | 6812 |
|
|
2017
Q1 | $3K | Sell |
1,097
-1,066
| -49% | -$3.02K | ﹤0.01% | 6367 |
|
|
2016
Q4 | $7K | Buy |
2,163
+1,803
| +501% | +$4.9K | ﹤0.01% | 6219 |
|
|
2016
Q3 | $1K | Hold |
360
| – | – | ﹤0.01% | 6317 |
|
|
2016
Q2 | $1K | Buy |
+360
| New | +$1.7K | ﹤0.01% | 6279 |
|
Other funds holding NAGE
SW
VCM
TCM
Royal Bank of Canada's NAGE Position: Q1 2026 in Review
Royal Bank of Canada reduced its Niagen Bioscience (NAGE) stake by 3.1% in Q1 2026, selling an estimated $21.3K and leaving 125,305 shares worth $553K. The position accounts for ﹤0.01% of the portfolio, ranked #4059.
Royal Bank of Canada first reported a position in NAGE in Q2 2016 and has held it in 38 quarters since. The position peaked at $1.19M in Q3 2025. 143 funds tracked by Wall St. Rank hold NAGE as of Q1 2026.
- Royal Bank of Canada held 125,305 shares of Niagen Bioscience worth $553K as of Q1 2026.
- Royal Bank of Canada sold 3,952 Niagen Bioscience shares in Q1 2026, an estimated $21.3K.
- Niagen Bioscience made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #4059 holding.
- Royal Bank of Canada first reported a position in Niagen Bioscience in Q2 2016 and has held it in 38 quarters since.
- Royal Bank of Canada's Niagen Bioscience position peaked at $1.19M in Q3 2025.
- 143 funds tracked by Wall St. Rank held Niagen Bioscience as of Q1 2026.
Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.